Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen.

Novo Nordisk is introducing a new cash-offer price of $299 available through July 31, 2025, and available for self-paying patients who are new to the Wegovy savings offer or those who have not ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing tactics and illegal compounding, risking patient safety.Novo Nordisk began ...

June 26 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

Novo Nordisk (NVO) partners with WeightWatchers to expand access to Wegovy through NovoCare Pharmacy after ending a deal with Hims & Hers (HIMS). Read more here.

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug. The Danish ...

Novo Nordisk (NVO) launches its blockbuster weight-loss drug Wegovy in India, shortly after rival Eli Lilly (LLY) introduced its popular weight loss/diabetes therapy Mounjaro in the country this ...

Hims & Hers’ stock price has swung wildly this year. The telehealth company’s public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday.